Drug Discovery at Neurogeneration

Neurogeneration has established a highly-focused drug discovery platform built on the company’s deep knowledge of inhibitors and inflammatory events as causative factors of synaptic damages triggered by ABeta oligomers  accumulation.

The companimg_02y’s lead compound, NGN-9 is currently undergoing pharmacokinetic and hit identification studies.

Neurogeneration selective novel small molecules therapy may become  a new treatment for progressive neurodegenerative changes at the synaptic and intra-neuronal levels.  Its pharmacokinetic profiles is being optimized to drive a robust therapeutic response in various pre-clinical models of Alzheimer’s disease and aging disorders prior to its use in clinical trials.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s